Clinical Trials Logo

Clinical Trial Summary

This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.


Clinical Trial Description

Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure, of which the measurement is invasive and therefore not suitable for routine clinical practice. The detection of serum biomarkers is potential for noninvasive diagnosis of portal hypertension in cirrhosis. However, many are still in the exploratory phases of testing and are not yet ready to enter clinical practice. This study prospectively enrolled participants in 6 liver centers (Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan Hospital, Beijing Friendship Hospital, Xingtai People's Hospital, and 302 Hospital of PLA) in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and HVPG in cirrhosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03713606
Study type Observational
Source Nanfang Hospital of Southern Medical University
Contact Xiaolong Qi, M.D.
Phone +86 18588602600
Email qixiaolong@vip.163.com
Status Recruiting
Phase
Start date September 30, 2018
Completion date June 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT02504034 - Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein N/A
Recruiting NCT02505152 - Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy N/A
Completed NCT02669875 - Serelaxin To Lower Portal Pressure Phase 2
Recruiting NCT04720456 - SHAPE of Portal Hypertension in Children Phase 2
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT02305914 - Follow-up Study of Complications of Acute Pancreatitis N/A
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Terminated NCT05282121 - A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Phase 2
Completed NCT00004641 - A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Phase 2
Completed NCT03138915 - Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701) N/A
Completed NCT03175731 - PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Phase 4
Active, not recruiting NCT04315571 - Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents N/A
Completed NCT03459378 - Outcome After TIPS
Recruiting NCT03470389 - Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM) N/A
Completed NCT02462967 - Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Phase 2
Active, not recruiting NCT01097811 - Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy N/A
Terminated NCT06082843 - A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Phase 2
Recruiting NCT03315767 - Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES) N/A
Terminated NCT05161481 - A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live Phase 2
Completed NCT03766880 - MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802) N/A